China: Food and Drugs Law

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

On August 28, 2024, the National Medical Products Administration (NMPA) released the Medical Device Administration Law (Draft for Comment)...